Ligase Targeting Drug Development Summit

Temas de la conferencia
The development of mono- and bivalent degraders continues to gain traction, but biopharma faces challenges in rapidly discovering, validating, and utilizing novel E3 ligases. This leaves therapeutic opportunities untapped due to obstacles in ligase screening, structural characterization, and assaying therapeutic efficacy.

Organizador profesional (PCO)
Hanson Wade

Observaciones
URL:
Brochure: https://go.evvnt.com/2174653-3?pid=4832

Speakers: Andreas Kraemer Principal Investigator Goethe University Frankfurt am Main and Structural Genomics Consortium, and more

https://go.evvnt.com/2174653-2?pid=4832

Ms. Isabella Hunter